Literature DB >> 11527008

The use of CpG DNA as a mucosal vaccine adjuvant.

M J McCluskie1, R D Weeratna, P J Payette, H L Davis.   

Abstract

CpG DNA has been shown to be a potent adjuvant in many disease models. Most studies using CpG DNA as adjuvant have used parenteral delivery, but more effective protection against mucosal pathogens could be achieved with effective mucosal immunization. Recently, mucosal immunization with CpG DNA as an adjuvant has been shown to induce both systemic (humoral and cellular) and mucosal antigen-specific immune responses. This review will concentrate on the use of CpG DNA as an adjuvant for the induction of mucosal immunity.

Mesh:

Substances:

Year:  2001        PMID: 11527008

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  2 in total

Review 1.  Adjuvants: Engineering Protective Immune Responses in Human and Veterinary Vaccines.

Authors:  Bassel Akache; Felicity C Stark; Gerard Agbayani; Tyler M Renner; Michael J McCluskie
Journal:  Methods Mol Biol       Date:  2022

2.  Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection.

Authors:  Linda J Berry; Danica K Hickey; Kathryn A Skelding; Shisan Bao; Amanda M Rendina; Philip M Hansbro; Christine M Gockel; Kenneth W Beagley
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.